SCHEMBL6927893

SCHEMBL6927893

O=C(Nc1ccccc1)c1ccc(OCc2ccccc2)nc1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 6/20 0.68
CXCR1 P25024 5/20 0.66
RAB9A P51151 5/20 0.62
NPC1 O15118 4/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
RXFP1 Q9HBX9 2/20 0.62
GABRA5 P31644 2/20 0.60
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.58
P4HTM Q9NXG6 1/20 0.57
CASP3 P42574 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SGMS2 Q8NHU3 1/20 0.55
NR1H4 Q96RI1 1/20 0.53
LMNA P02545 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2158636 0.91 CXCR2 (0.80) CXCR2CXCR1MEN1KMT2ARXFP1
SCHEMBL12398727 0.91 CXCR2 (0.63) CXCR2CXCR1RAB9ANPC1MEN1
SCHEMBL12398730 0.88 MEN1 (0.62) CXCR2CXCR1RAB9ANPC1MEN1
SCHEMBL6929856 0.88 CXCR2 (0.67) CXCR2CXCR1RAB9ANPC1NR1H4
SCHEMBL12173108 0.86 RAB9A (0.66) CXCR2CXCR1RAB9ANPC1MEN1
SCHEMBL28703922 0.86 CXCR2 (0.64) CXCR2CXCR1
SCHEMBL19074879 0.84 CXCR1 (0.64) CXCR2CXCR1RAB9ANPC1GABRA5
SCHEMBL6929221 0.84 CXCR2 (0.63) CXCR2CXCR1RAB9ANPC1MEN1
SCHEMBL6927775 0.84 CXCR2 (0.73) CXCR2CXCR1RAB9ANPC1MEN1
SCHEMBL6930905 0.83 RAB9A (0.70) CXCR2CXCR1RAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
WO-2011035324-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS VANDERBILT UNIVERSITY (US) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS GRM5, GRIK5, GRM1 CXCR2 2454/4885CXCR1 2582/4885RAB9A 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.